Rhythm Pharmaceuticals announced the appointment of Alastair “Al” Garfield, Ph.D. as Chief Scientific Officer, effective July 1. Garfield rejoins Rhythm after serving as Senior Vice President and Head of Translational Sciences and Strategy at Rectify Pharma, where he helped deliver first-in-class therapeutics for rare disease.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RYTM:
- Rhythm Pharmaceuticals Receives Positive CHMP Opinion for ▼IMCIVREE® (setmelanotide) for the Treatment of Obesity and Control of Hunger in Patients between 2 and 6 years old with Bardet Biedl Syndrome or POMC, PCSK1, or LEPR Deficiency
- Rhythm Pharmaceuticals receives positive CHMP opinion for IMCIVREE
- Rhythm Pharmaceuticals Announces New Employment Inducement Grants
- Rhythm: Patient-reported experiences with hyperphagia in HO presented at ENDO
- Rhythm Pharmaceuticals Presents Patient-reported Experiences with Hyperphagia in Hypothalamic Obesity at ENDO 2024